Return to Table of Contents
Bates DW. Drugs and adverse drug reactions: how worried should we be? JAMA 1998;279:1216-7.
Berwick, D. A User's Manual For The IOM's 'Quality Chasm' Report Health Affairs 2002; 21:80-90Christensen DB, Penna PM. Quality assessment and quality assurance of pharmacy services. Journal of Managed Care Pharmacy 1995;1:40-51.
Cipolle, R., Strand L.M., Morley, P. Identifting, resolving and preventing drug therapy problems. Ch. 3 In: Pharmaceutical Care Practice. McGraw-Hill 1998.
Coons SJ, Kaplan RM. Quality of life assessment: understanding its use as an outcome measure. Hospital Formulary 1993; 28: 486-98.
Coye, M.J. No Toyotas in health care: why
health care has not evolved to meet patients' needs. Health Aff.(Millwood.)
20 (6):44-56, 2001.
Dombrowski SR. Pharmacist counseling on nutrition and physical
activity - part 1 of 2: understanding current guidelines. Journal of the
American Pharmaceutical Association 1999;39:479-91.
Florida Administrative Code 64B8-9-013 Standards for the Use of Controlled Substances for Treatment of Pain.
Hagland M. Is there any solution to the drug problem? California Medicine; December, 1998.
Hepler C. D. Clozapine and the outmoded drug use process. Am Pharmacy NS30:39-40, 1990.
Hepler C. D. Regulating for Outcomes as a
Systems Response to the Problem of Drug-Related Morbidity. J Am Pharm Assoc
41 (No. 1):108-115, 2001.
Hepler CD. Pharmacy as a clinical profession.
Hepler CD, Grainger-Rousseau T-J. Pharmaceutical care versus traditional drug treatment: is there a difference?Drugs 1995;49:1-10.
Hepler C. D. and R. Segal. Preventing medication errors and improving drug therapy outcomes through system management, Boca Raton, FL:CRC Press, 2003, Preliminaries and Ch. 1-4.
H. Herborg, et al. Improving Drug Therapy for Patients with Asthma--Part 1: Patient Outcomes. J.Am.Pharm Assoc. 41 (July-Aug):539-550, 2001.
H. Herborg, et al.. Improving Drug Therapy
for Patients with Asthma--Part II: Use of Antiasthma Medications. J.Am.Pharm
Assoc. 41 (July-Aug):551-559, 2001.
Jolicoeur LM, Jones-Grizzle AJ, Boyer G. Guidelines
for performing a pharmacoeconomic analysis. American Journal of Hospital
Pharmacy 1992;49:1741-7.
Johnson JA, Bootman JL. Drug-related morbidity and mortality: a cost-of-illness model. Archives of Internal Medicine 1995;155:1949-56.
Karlsson G, Johannesson M. The decision rules of cost-effectiveness analysis. Pharmacoeconomics 1996;9:113-120. (Technical in-depth discussion of incremental cost analysis.)
Knox RA, Mooney B. Hospital dosage mistakes not rare - past cases reveal medication errors. The Boston Globe; April 16, 1995, Sunday, City Edition.
Knox RA, Golden D. Drug dosage was questioned Dana-Farber pharmacist sent order back to doctor in breast cancer case. The Boston Globe; Monday, June 19, 1995.
Kong D. Safeguards failed at Dana-Farber - fatal chemotherapy dosages slipped through hospital's computer system. The Boston Globe; Saturday, March 25, 1995.
MacKinnon N. Performance measures in ambulatory pharmacy. Pharm. Pract. Management Q. 1997;17:52-62.
MacKinnon N. J. and C. D. Hepler. Preventable drug-related morbidity in older adults 1. Indicator development. J.Manage.Care Pharm. 8 (Sep/Oct):365-371, 2002.
MacKinnon N. Jand C. D. Hepler. Indicators
of Preventable Drug-Related Morbidity in Older Adults II. Use in a Managed Care
Organization. J.Manage.Care Pharm. 9 (2):134-141, 2003.
Morris, C. J, J. A. Cantrill, C. D.
Hepler, et al. Preventing drug-related morbidity-determining
valid indicators. International Society for Quality in Health Care and Oxford
University Press 14 (No. 3):183-197, 2002.
Pham A. Tufts HMO to double copayments for
top drugs. The Boston Globe; April 2, 1999.
Pham A. Harvard to alter how members pay for pills: copayments could reach $30 or more. The Boston Globe; June 12, 1999.
Ruth LC, Detmer EJ. Assessing health plan quality. Benefits Quarterly 1995 Second Quarter, 32-6.
Sanchez L. Pharmacoeconomic principles and methods: including pharmacoeconomics into hospital pharmacy practice. Hospital Pharmacy 1994;29:1035-40.
Schwartz RK, Soumerai SB, Avorn J. Physician motivations for nonscientific drug prescribing. Social Science & Medicine 1989;28:577-82.
Sleath B, Collins T, Kelly HW et al.Effect of including both physicians and pharmacists in an asthma drug use review intervention. American Journal of Health-System Pharmacists 1997;54:2197-200.
Segal R, Wang F. Influencing physician prescribing. Pharm. Practice Management Q. 1999;9:30-50
Smith M, Juergens J, Jack W. Medication and the quality of life. American Pharmacy 1991;NS31(4):27-33.
Soumerai SB, Ross-Degnan D, Avorn J et al. Effects of medicaid drug-payment limits on admissions to hospitals and nursing homes. New England Journal of Medicine 1991;325:1072-7.
Szasz TS, Hollender MH. The basic models of the doctor-patient relationship. In: HD Schwartz & CS Kart (eds.), Dominant Issues in Medical Sociology (pp. 100-107), Reading, MA: Addison-Wesley.
Tamblyn R. et al. Adverse events associated with prescription drug cost-sharing among . . . JAMA 2001;285:4219
Tan GH, Nelson RL. Pharmacologic treatment options for non-insulin-dependent diabetes mellitus. Mayo Clinic Proceedings 1996;71:763-8.
Wilt VM, Gums JG, Ahmed
OI, Moore LM. Outcome analysis of a pharmacist-managed anticoagulation
service. Pharmacotherapy 1995;15:732-9.
Last modified July 5 2003